advanced search

Welcome: Guest

log in

Generics in Germany

Generics

Publication Date September 2009
Publisher Datamonitor
Product Type Report
Pages 30
ISBN Number not applicable
Product Code DAT00880
Buy this product or for assistance call +44 20 7060 7474

Summary

Datamonitor's Generics in Germany industry profile is an essential resource for top-level data and analysis covering the generics industry. It includes detailed data on market size and segmentation, plus textual and graphical analysis of the key trends and competitive landscape, leading companies and demographic information.

Scope

  • Contains an executive summary and data on value, volume and/or segmentation
  • Provides textual analysis of the industry's recent performance and future prospects
  • Incorporates in-depth five forces competitive environment analysis and scorecards
  • Includes a five-year forecast of the industry
  • The leading companies are profiled with supporting key financial metrics
  • Supported by the key macroeconomic and demographic data affecting the market

Highlights

  • Detailed information is included on market size, measured by value and/or volume
  • Five forces scorecards provide an accessible yet in depth view of the market's competitive landscape

Why you should buy this report

  • Spot future trends and developments
  • Inform your business decisions
  • Add weight to presentations and marketing materials
  • Save time carrying out entry-level research

Market Definition

The generics market consists of all sales of generic drugs for human use at ex-manufacturer prices. Datamonitor defines a generic as an officially-approved copy of an original product whose patent has expired, marketed either as a brand or using the generic name.

This definition excludes multi-source copy products, that make up much of markets such as India, Spain and Italy. Multi-source copies are drugs still under patent that are offered by manufacturers other than the patent holders. All currency conversions have been calculated at constant 2008 average exchange rates.

For the purpose of this report Europe is deemed to comprise of Belgium, the Czech Republic, Denmark, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Romania, Russia, Spain, Sweden, the Ukraine and the United Kingdom.

Content

  • Executive Summary
  • Chapter 1 Market Overview
    • 1.1 Market Definition
    • 1.2 Research Highlights
    • 1.3 Market Analysis
  • Chapter 2 Market Value
  • Chapter 3 Market Segmentation I
  • Chapter 4 Market Segmentation Ii
  • Chapter 5 Five Forces Analysis
    • 5.1 Summary
    • 5.2 Buyer Power
    • 5.3 Supplier Power
    • 5.4 New Entrants
    • 5.5 Substitutes
    • 5.6 Rivalry
  • Chapter 6 Leading Companies
    • 6.1 Ratiopharm Group
    • 6.2 HEXAL AG
    • 6.3 STADA Arzneimittel AG
    • 6.4 Mylan Laboratories Inc
  • Chapter 7 Market Forecasts
    • 7.1 Market Value Forecast
  • Chapter 8 Macroeconomic Indicators
  • Chapter 9 Appendix
    • 9.1 Methodology
    • 9.2 Industry Associations
    • 9.3 Related Datamonitor Research
  • List of Tables
    • Table 1: Germany Generics Market Value: $ billion, 2004-2008
    • Table 2: Germany Generics Market Segmentation I: % Share, by Value, 2008
    • Table 3: Germany Generics Market Segmentation II: % Share, by Value, 2008
    • Table 4: Key Facts: Ratiopharm Group
    • Table 5: Key Facts: HEXAL AG
    • Table 6: Key Facts: STADA Arzneimittel AG
    • Table 7: Key Financials: STADA Arzneimittel AG
    • Table 8: Key Facts: Mylan Laboratories Inc
    • Table 9: Key Financials: Mylan Laboratories Inc
    • Table 10: Germany Generics Market Value Forecast: $ billion, 2008-2013
    • Table 11: Germany Size of Population (million) , 2004-2008
    • Table 12: Germany GDP (Constant 2000 Prices, $ billion), 2004-2008
    • Table 13: Germany Inflation, 2004-2008
    • Table 14: Germany Exchange Rate, 2004-2008
Delivery Details

PDF:Delivered by email usually within 4 to 8 UK business hours.

Industry Events

2nd International Conference on Drug Discovery and Therapy

01 Feb 10 to 04 Feb 10
Dubai, United Arab Emirates
view summary >>

Oncology Market & Patient Access

14 Dec 09 to 16 Dec 09
Prague, Czech Republic
view summary >>

Orphan & Ultra Orphan Drugs

13 Jan 10 to 14 Jan 10
Brussels, Belgium
view summary >>